80 related articles for article (PubMed ID: 11510521)
1. Urine detection of survivin and diagnosis of bladder cancer.
Moore M
J Insur Med; 2001; 33(2):202-3. PubMed ID: 11510521
[No Abstract] [Full Text] [Related]
2. Contribution of the prostate limits the usefulness of survivin for the detection of bladder cancer.
Davies B; Chen J; Modugno F; Weissfeld J; Landsittel D; Dhir R; Nelson J; Getzenberg RH
J Urol; 2005 Nov; 174(5):1767-70. PubMed ID: 16217280
[TBL] [Abstract][Full Text] [Related]
3. Survivin mRNA expression in urine as a biomarker for patients with transitional cell carcinoma of bladder.
Hou JQ; He J; Wen DG; Chen ZX; Zeng J
Chin Med J (Engl); 2006 Jul; 119(13):1118-20. PubMed ID: 16834932
[No Abstract] [Full Text] [Related]
4. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer.
Moussa O; Abol-Enein H; Bissada NK; Keane T; Ghoneim MA; Watson DK
J Urol; 2006 Jun; 175(6):2312-6. PubMed ID: 16697865
[TBL] [Abstract][Full Text] [Related]
5. Bladder cancer diagnosis and recurrence prognosis: comparison of markers with emphasis on survivin.
Schultz IJ; Witjes JA; Swinkels DW; de Kok JB
Clin Chim Acta; 2006 Jun; 368(1-2):20-32. PubMed ID: 16480698
[TBL] [Abstract][Full Text] [Related]
6. Comparison of seven screening methods in the diagnosis of bladder cancer.
Sun Y; He DL; Ma Q; Wan XY; Zhu GD; Li L; Luo Y; He H; Yang L
Chin Med J (Engl); 2006 Nov; 119(21):1763-71. PubMed ID: 17097029
[TBL] [Abstract][Full Text] [Related]
7. Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy.
Kitamura H; Torigoe T; Honma I; Asanuma H; Nakazawa E; Shimozawa K; Hirohashi Y; Sato E; Sato N; Tsukamoto T
Urology; 2006 May; 67(5):955-9. PubMed ID: 16635519
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of BTA stat, cytology, and survivin in bladder cancer surveillance over 5 years in patients with spinal cord injury.
Davies B; Chen JJ; McMurry T; Landsittel D; Lewis N; Brenes G; Getzenberg RH
Urology; 2005 Oct; 66(4):908-11. PubMed ID: 16230180
[TBL] [Abstract][Full Text] [Related]
10. [Urine-based oncological diagnostic for bladder carcinoma: what is new?].
Rübben H
Urologe A; 2009 Jun; 48(6):597. PubMed ID: 19557463
[No Abstract] [Full Text] [Related]
11. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer.
Yu J; Zhu T; Wang Z; Zhang H; Qian Z; Xu H; Gao B; Wang W; Gu L; Meng J; Wang J; Feng X; Li Y; Yao X; Zhu J
Clin Cancer Res; 2007 Dec; 13(24):7296-304. PubMed ID: 18094410
[TBL] [Abstract][Full Text] [Related]
12. The simultaneous use of telomerase, cytokeratin 20 and CD4 for bladder cancer detection in urine.
Siracusano S; Niccolini B; Knez R; Tiberio A; Benedetti E; Bonin S; Ciciliato S; Pappagallo GL; Belgrano E; Stanta G
Eur Urol; 2005 Mar; 47(3):327-33. PubMed ID: 15716196
[TBL] [Abstract][Full Text] [Related]
13. Primary application study in early diagnosis of bladder cancer by survivin molecular beacons.
Zhao J; He D; He H; Li L; Zhang LL; Wang XY
Urology; 2007 Jul; 70(1):60-4. PubMed ID: 17656209
[TBL] [Abstract][Full Text] [Related]
14. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome.
Hausladen DA; Wheeler MA; Altieri DC; Colberg JW; Weiss RM
J Urol; 2003 Jul; 170(1):230-4. PubMed ID: 12796695
[TBL] [Abstract][Full Text] [Related]
15. Telomerase activity in urine sediments as a tool for noninvasive detection of bladder cancer.
Dettlaff-Pokora A; Matuszewski M; Schlichtholz B
Cancer Lett; 2005 May; 222(1):83-8. PubMed ID: 15837544
[TBL] [Abstract][Full Text] [Related]
16. Can a point-of-care urine protein assay monitor bladder cancer recurrence?
O'donnell MA
Nat Clin Pract Oncol; 2006 Sep; 3(9):482-3. PubMed ID: 16955086
[No Abstract] [Full Text] [Related]
17. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
[TBL] [Abstract][Full Text] [Related]
18. The use of urine-based biomarkers in bladder cancer.
Grossman HB; Blute ML; Dinney CP; Jones JS; Liou LS; Reuter VE; Soloway MS
Urology; 2006 Mar; 67(3 Suppl 1):62-4. PubMed ID: 16530080
[No Abstract] [Full Text] [Related]
19. Urine detection of survivin and diagnosis of bladder cancer.
Smith SD; Wheeler MA; Plescia J; Colberg JW; Weiss RM; Altieri DC
JAMA; 2001 Jan; 285(3):324-8. PubMed ID: 11176843
[TBL] [Abstract][Full Text] [Related]
20. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
